Idelvion®作为血友病B的现代治疗选择(赞助商:CSL Behring GmbH)

Thieme Case Report Pub Date : 2020-01-22 DOI:10.1055/a-1019-1794

{"title":"Idelvion®作为血友病B的现代治疗选择(赞助商:CSL Behring GmbH)","authors":"","doi":"10.1055/a-1019-1794","DOIUrl":null,"url":null,"abstract":"Zusammenfassung Idelvion® (albutrepenonacog alfa, rIX-FP) is a long-acting recombinant factor IX (FIX) albumin fusion protein indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B. It allows prophylaxis intervals of up to 14 days.* Compared with previous therapy, this fusion protein allows for a significant reduction in injection frequency while maintaining a favourable efficacy and safety profile.","PeriodicalId":113005,"journal":{"name":"Thieme Case Report","volume":"100 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Idelvion® as a modern treatment option for haemophilia B (Sponsor: CSL Behring GmbH)\",\"authors\":\"\",\"doi\":\"10.1055/a-1019-1794\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Zusammenfassung Idelvion® (albutrepenonacog alfa, rIX-FP) is a long-acting recombinant factor IX (FIX) albumin fusion protein indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B. It allows prophylaxis intervals of up to 14 days.* Compared with previous therapy, this fusion protein allows for a significant reduction in injection frequency while maintaining a favourable efficacy and safety profile.\",\"PeriodicalId\":113005,\"journal\":{\"name\":\"Thieme Case Report\",\"volume\":\"100 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thieme Case Report\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-1019-1794\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thieme Case Report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-1019-1794","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Zusammenfassung Idelvion®(albutrepenonacog alfa, rIX-FP)是一种长效重组因子IX (FIX)白蛋白融合蛋白，用于治疗和预防b型血友病患者出血，预防间隔长达14天。*与以前的治疗方法相比，这种融合蛋白可以显著减少注射频率，同时保持良好的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Idelvion® as a modern treatment option for haemophilia B (Sponsor: CSL Behring GmbH)

Zusammenfassung Idelvion® (albutrepenonacog alfa, rIX-FP) is a long-acting recombinant factor IX (FIX) albumin fusion protein indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B. It allows prophylaxis intervals of up to 14 days.* Compared with previous therapy, this fusion protein allows for a significant reduction in injection frequency while maintaining a favourable efficacy and safety profile.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Thieme Case Report

自引率

0.00%

发文量